# Taurolidine in Treating Patients With Recurrent or Progressive Glioma

> **NCT00022360** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** taurolidine

## Key facts

- **NCT ID:** NCT00022360
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2001-10
- **Final completion:** 2001-10
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022360, "Taurolidine in Treating Patients With Recurrent or Progressive Glioma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00022360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*